Page results
-
Information about community sickle cell and thalassaemia services provided via UCLH.
-
Gastro-oesophageal reflux (GOR) is the effortless regurgitation of feeds/milk. It affects over 40% of babies.
-
This information is for patients who are having radiotherapy for a base of skull tumour. It explains what the treatment involves, describes side-effects you may experience during and after treatment, and how best to cope with them.
-
Information about Lutetium-177 PSMA radionuclide therapy for metastatic or treatment-resistant prostate cancer
-
This information has been written for patients who are having radiotherapy treatment to the brain and spine.
-
Info about our regular, online origami club for people under the care of UCLH for cancer or a blood condition
-
UCLH is the only Supra-Centre in England to deliver Intracranial Stereotactic Radiosurgery and Stereotactic Radiotherapy Services (SRS/SRT) as part of an integrated neurosurgical and Neuro-oncology service to patients.
-
Our nationally-recognised service helps children and young people (up to 19 years) with type 1 diabetes, type 2 diabetes, monogenic diabetes such as maturity onset diabetes in the young (MODY) and steroid related diabetes.
-
A clinic for neurology patients with long COVID
-
Mr Ruwan Wimalasundera is a senior consultant obstetrician and fetal medicine specialist at UCLH. He manages all aspects of pregnancy, including both low -risk and high-risk pregnancies, especially older mothers and multiple pregnancies
File results
-
FOI/2022/0145 - Head and neck cancer drug treatments
-
FOI/2022/0147 - Oesophageal and gastric cancer drug treatments
-
FOI/2022/0148 - Maternity related overseas services
-
FOI/2022/0150 - Hepatocellular carcinoma drug treatments
-
FOI/2022/0151 - Omnipod patch pump
-
FOI/2022/0153 - Central water treatment equipment for renal dialysis
-
FOI/2022/0154 - Immunoglobulin treatments (for any disease)
-
FOI/2022/0155 - Patient hospital bedside and electronic patient notes
-
FOI/2022/0161 - Referral to treatment waiting times
-
FOI/2022/0167 - Prostate cancer drug treatments